FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alan Wakeling

Research Profile

Chemicals & Drugs

Disorders

Breast Neoplasms

Physiology

Anatomy

Phenomena

Phosphorylation

Procedures

Reverse Transcriptase Polymerase Chain Reaction

Co-author Network

Publications

TOP 3
J M W Gee; A Howell; W J Gullick; C C Benz; R L Sutherland; R J Santen; L-A Martin; F Ciardiello; W R Miller; M Dowsett; P Barrett-Lee; J F R Robertson; S R Johnston; Helen E Jones; Alan E Wakeling; R Duncan; Robert I Nicholson
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.
Helen E Jones; Lindy Goddard; J M W Gee; Stephen Hiscox; M Rubini; Denise Barrow; Janice M Knowlden; S Williams; Alan E Wakeling; Robert I Nicholson
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Nicola J Jordan; J M W Gee; Denise Barrow; Alan E Wakeling; Robert I Nicholson
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alan Wakeling (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: J M W Gee; A Howell; W J Gullick; C C Benz; R L Sutherland; R J Santen; L-A Martin; F Ciardiello; W R Miller; M Dowsett; P Barrett-Lee; J F R Robertson; S R Johnston; Helen E Jones; Alan E Wakeling; R Duncan; Robert I Nicholson
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.
Endocrine-related cancer 2005;12 Suppl 1():S1-7.
2004: Helen E Jones; Lindy Goddard; J M W Gee; Stephen Hiscox; M Rubini; Denise Barrow; Janice M Knowlden; S Williams; Alan E Wakeling; Robert I Nicholson
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Endocrine-related cancer 2004;11(4):793-814.
2004: Nicola J Jordan; J M W Gee; Denise Barrow; Alan E Wakeling; Robert I Nicholson
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Breast cancer research and treatment 2004;87(2):167-80.
2004: Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan E Wakeling; Robert I Nicholson
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
Clinical & experimental metastasis 2004;21(3):201-12.
2003: J M W Gee; Maureen E Harper; Iain R Hutcheson; Tracie-Ann Madden; Denise Barrow; Janice M Knowlden; Richard A McClelland; Nicola J Jordan; Alan E Wakeling; Robert I Nicholson
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Endocrinology 2003;144(11):5105-17.
2003: Iain R Hutcheson; Janice M Knowlden; Tracie-Ann Madden; Denise Barrow; J M W Gee; Alan E Wakeling; Robert I Nicholson
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Breast cancer research and treatment 2003;81(1):81-93.
2003: Janice M Knowlden; Iain R Hutcheson; Helen E Jones; Tracieann Madden; J M W Gee; Maureen E Harper; Denise Barrow; Alan E Wakeling; Robert I Nicholson
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Endocrinology 2003;144(3):1032-44.
2002: Robert I Nicholson; Iain R Hutcheson; Maureen E Harper; Janice M Knowlden; Denise Barrow; Richard A McClelland; Helen E Jones; Alan E Wakeling; J M W Gee
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
Annals of the New York Academy of Sciences 2002;963():104-15.
2002: Maureen E Harper; Lindy Goddard; Eve Glynne-Jones; Jean Assender; Carol M Dutkowski; Denise Barrow; Odette L Dewhurst; Alan E Wakeling; Robert I Nicholson
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
The Prostate 2002;52(1):59-68.
2001: Alan E Wakeling; Robert I Nicholson; J M W Gee
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4350s-4355s; discussion 4411s-4412s.
2001: J F Robertson; R I Nicholson; N J Bundred; E Anderson; Z Rayter; M Dowsett; J N Fox; J M W Gee; A Webster; Alan E Wakeling; C Morris; M Dixon
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
Cancer research 2001;61(18):6739-46.
2001: Robert I Nicholson; Iain R Hutcheson; Maureen E Harper; Janice M Knowlden; Denise Barrow; Richard A McClelland; Helen E Jones; Alan E Wakeling; J M W Gee
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
Endocrine-related cancer 2001;8(3):175-82.
1997: Helen E Jones; Carol M Dutkowski; Denise Barrow; Maureen E Harper; Alan E Wakeling; Robert I Nicholson
New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145.
International journal of cancer. Journal international du cancer 1997;71(6):1010-8.